Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BVS Bioventus	$7.08 -1.8%	$6.77	$5.81 ▼ $14.38	$585.37M	0.83	397,853 shs	365,631 shs
CATX Perspective Therapeutics	$3.56 +5.3%	$3.78	$1.60 ▼ $16.55	$264.38M	1.17	942,412 shs	485,276 shs
INFU InfuSystem	$9.61 +0.1%	$6.65	$4.61 ▼ $9.97	$196.29M	1.81	168,401 shs	274,134 shs
LLIT Lianluo Smart	$110.64 +23.8%	$9.91	$2.76 ▼ $17.14	$244.63M	0.16	1.04 million shs	1.60 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BVS Bioventus	-1.50%	-4.25%	+14.44%	+10.75%	-12.07%
CATX Perspective Therapeutics	-1.17%	-11.29%	-21.58%	+34.66%	-77.18%
INFU InfuSystem	-0.21%	+3.00%	+74.23%	+65.52%	+39.13%
LLIT Lianluo Smart	-16.54%	+21.40%	+202.54%	+1,465.67%	+10,556.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BVS Bioventus	3.087 of 5 stars	3.4	0.0	0.0	0.0	2.1	3.3	1.3
CATX Perspective Therapeutics	1.5567 of 5 stars	3.6	1.0	0.0	0.0	1.9	0.8	0.0
INFU InfuSystem	3.4051 of 5 stars	2.0	5.0	0.0	0.0	2.4	4.2	1.9
LLIT Lianluo Smart	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BVS Bioventus	2.75	Moderate Buy	$13.75	94.21% Upside
CATX Perspective Therapeutics	3.18	Buy	$12.56	252.68% Upside
INFU InfuSystem	4.00	Strong Buy	$12.50	30.07% Upside
LLIT Lianluo Smart	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest LLIT, BVS, CATX, and INFU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/22/2025	INFU InfuSystem	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
7/21/2025	INFU InfuSystem	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/12/2025	CATX Perspective Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/7/2025	BVS Bioventus	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
6/23/2025	CATX Perspective Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $12.00
6/23/2025	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00
6/3/2025	CATX Perspective Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$15.00 ➝ $16.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BVS Bioventus	$564.14M	1.04	$0.56 per share	12.58	$2.80 per share	2.53
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	$2.67 per share	N/A
INFU InfuSystem	$139.89M	1.40	$0.75 per share	12.79	$2.47 per share	3.89
LLIT Lianluo Smart	$380K	643.75	N/A	N/A	($0.59) per share	-187.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BVS Bioventus	-$156.23M	N/A	N/A	15.39	N/A	-7.11%	15.61%	4.01%	N/A
CATX Perspective Therapeutics	-$46.51M	N/A	0.00	N/A	N/A	-4,096.66%	-27.40%	-23.16%	N/A
INFU InfuSystem	$870K	$0.23	160.19	31.00	N/A	1.12%	2.78%	1.41%	N/A
LLIT Lianluo Smart	-$4.45M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BVS Bioventus	N/A	N/A	N/A	N/A	N/A
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	N/A
INFU InfuSystem	N/A	N/A	N/A	N/A	N/A
LLIT Lianluo Smart	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BVS Bioventus	1.85	1.41	0.99
CATX Perspective Therapeutics	N/A	9.60	9.60
INFU InfuSystem	0.50	1.98	1.59
LLIT Lianluo Smart	N/A	2.42	2.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BVS Bioventus	62.94%
CATX Perspective Therapeutics	54.66%
INFU InfuSystem	71.13%
LLIT Lianluo Smart	28.75%

Insider Ownership

Company	Insider Ownership
BVS Bioventus	33.00%
CATX Perspective Therapeutics	3.72%
INFU InfuSystem	10.20%
LLIT Lianluo Smart	22.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BVS Bioventus	1,200	82.68 million	54.46 million	Not Optionable
CATX Perspective Therapeutics	70	74.26 million	65.21 million	Optionable
INFU InfuSystem	410	20.43 million	19.10 million	Optionable
LLIT Lianluo Smart	6	2.21 million	N/A	Not Optionable

LLIT, BVS, CATX, and INFU Headlines

Recent News About These Companies

Best smart TVs in India 2024: Here's a list of the top 10 picks for amazing picture and sound quality

October 31, 2024 | livemint.com

How LG Is Making Smart Appliances Even Smarter

October 22, 2024 | forbes.com

The best smart rings for 2024

October 18, 2024 | popsci.comP

Get Smart or Get Indicted: Corporate Compliance in the Age of AI

October 9, 2024 | law.comL

Tragic Details About Jean Smart

October 9, 2024 | msn.com

5 Best Smart Locks of October 2024

October 9, 2024 | newsweek.comN

Li Auto reportedly to tape out in-house developed smart driving chip by end of 2024

October 7, 2024 | digitimes.comD

Don't miss out on this top-tier smart thermostat that's now hit an all-time low price

October 5, 2024 | androidpolice.comA

Samsung is turning your Galaxy phone into a smart door key

October 3, 2024 | msn.com

The coolest thing about smart glasses is not the AR. It’s the AI.

October 2, 2024 | technologyreview.comT

The Download: smart glasses, and tiny AI models

October 1, 2024 | technologyreview.comT

‘Saturday Night Live’: Jean Smart Kicks Off Season 50 With Best Premiere Audience In 4 Years

September 30, 2024 | msn.com

Top 10 Jean Smart movies and TV shows: The Hacks and SNL star’s top roles, explored

September 30, 2024 | msn.com

Jean Smart ushers in Season 50 of ‘SNL,’ with Maya Rudolph and special guests in cold open

September 29, 2024 | latimes.com

‘Saturday Night Live’ launches 50th season with Jean Smart, Jelly Roll and maybe Maya as Kamala

September 28, 2024 | apnews.comA

The best smart lock you can buy is now down to an all-time low price

September 21, 2024 | androidpolice.comA

With the Bullishness Baked In, Take the Smart Bet with Intuitive Machines (LUNR)

September 20, 2024 | msn.com

Jean Smart’s Response To Landing The SNL Guest Gig Is Lovely (And I Wish All Stars Were This Enthusiastic)

September 19, 2024 | msn.com

Saturday Night Live Announces Season 50 Lineup Including Jean Smart, Ariana Grande and Chappell Roan

September 18, 2024 | people.comP

Review: The LIFX A21 SuperColor Smart Light is the affordable Hue alternative you're looking for

September 15, 2024 | androidpolice.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LLIT, BVS, CATX, and INFU Company Descriptions

Bioventus NYSE:BVS

$7.08 -0.13 (-1.80%)

Closing price 04:00 PM Eastern

Extended Trading

$7.08 0.00 (-0.07%)

As of 06:43 PM Eastern

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Perspective Therapeutics NYSE:CATX

$3.56 +0.18 (+5.33%)

Closing price 04:00 PM Eastern

Extended Trading

$3.56 0.00 (0.00%)

As of 05:41 PM Eastern

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

InfuSystem NYSE:INFU

$9.61 +0.01 (+0.10%)

Closing price 04:00 PM Eastern

Extended Trading

$9.62 +0.01 (+0.05%)

As of 04:10 PM Eastern

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

Lianluo Smart NASDAQ:LLIT

Lianluo Smart Limited, together with its subsidiaries, designs, develops, markets, and distributes medical products primarily in China and internationally. The company offers medical devices, including wearable sleep respiratory solutions, general hospital products, medical compressors, and related supporting products. It also provides technical services in relation to the detection and analysis of obstructive sleep apnea syndrome to hospitals and medical centers through medical wearable devices. In addition, the company distributes medical products, such as sleep apnea machines. Lianluo Smart Limited sells its products primarily through distributors; and directly to hospitals, physical examination centers, and sleep centers, as well as to individual consumers. The company was formerly known as Dehaier Medical Systems Limited and changed its name to Lianluo Smart Limited in November 2016. Lianluo Smart Limited was incorporated in 2003 and is headquartered in Beijing, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time